{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Denali Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"DNLI"},"Address":{"label":"Address","value":"161 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, California, 94080, United States"},"Phone":{"label":"Phone","value":"+1 650 866-8548"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others."},"CompanyUrl":{"label":"Company Url","value":"https://www.denalitherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alexander O. Schuth","title":"Secretary, Chief Operating & Financial Officer"},{"name":"Carole Ho","title":"Chief Medical Officer & Head-Development"},{"name":"Dana Andersen","title":"CTO & Chief Manufacturing Officer"},{"name":"Joe Lewcock","title":"Chief Scientific Officer"},{"name":"Ryan J. Watts","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}